A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age Children

Azmi Nasser, Tesfaye Liranso, Toyin Adewole, Nicholas Fry, Joseph T. Hull, Fatima Chowdhry, Gregory D. Busse, Andrew J. Cutler, Nandita Joshi Jones, Robert L. Findling, Stefan Schwabe

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Fingerprint

Dive into the research topics of 'A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age Children'. Together they form a unique fingerprint.

Medicine & Life Sciences